×
About 11,070 results

ALLMedicine™ Cholangitis Center

Research & Reviews  3,693 results

Noncirrhotic Portal Hypertension in Primary Biliary Cholangitis with Coexisting CREST S...
https://doi.org/10.1016/j.clinre.2023.102114
Clinics and Research in Hepatology and Gastroenterology; Malkani KV, Jesudian AB et. al.

Mar 27th, 2023 - Primary Biliary Cholangitis (PBC) is an autoimmune liver disease that is sometimes associated with CREST (calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia) syndrome. If left untreated, PBC eventually prog...

Endogenous Endophthalmitis from a Klebsiella Pneumoniae Liver Abscess: The Incidence, R...
https://doi.org/10.1016/j.ajo.2023.03.009
American Journal of Ophthalmology; Kim E, Byon I et. al.

Mar 25th, 2023 - We investigated the rate of ophthalmologic examinations to detect endogenous endophthalmitis in patients with pyogenic liver abscesses (PLAs) and the incidence and risk factors of endophthalmitis from a PLA caused by Klebsiella pneumoniae (PLA-K)....

Risks factors associated with the development of Crohn's disease after ileal pouch-anal...
https://doi.org/10.1093/ecco-jcc/jjad051
Journal of Crohn's & Colitis; Fadel MG, Geropoulos G et. al.

Mar 25th, 2023 - Following ileal pouch-anal anastomosis (IPAA) for ulcerative colitis (UC), up to 16% of patients develop Crohn's disease of the pouch (CDP) which is a major cause of pouch failure. This systematic review and meta-analysis aimed to identify preoper...

Unraveling the Mechanisms Underlying Primary Sclerosing Cholangitis Through a Multidisciplinary, Integrative Research Approach
https://clinicaltrials.gov/ct2/show/NCT04685200

Mar 23rd, 2023 - Study Description: We hypothesize that primary sclerosing cholangitis (PSC) develops as a consequence of a genetically driven aberrant immune response to commensal or pathogenic bacteria, and that unique genetic-immunemicrobial associations may un...

A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness
https://clinicaltrials.gov/ct2/show/NCT05014672

Mar 21st, 2023 - The primary objective of this study is to evaluate the effect of setanaxib on biochemical response at Week 52 in participants with primary biliary cholangitis (PBC) and with elevated liver stiffness and intolerance or inadequate response to ursode...

see more →

Guidelines  23 results

EASL Clinical Practice Guidelines on sclerosing cholangitis.
https://doi.org/10.1016/j.jhep.2022.05.011
Journal of Hepatology; ,

Jun 24th, 2022 - Management of primary or secondary sclerosing cholangitis is challenging. These Clinical Practice Guidelines have been developed to provide practical guidance on debated topics including diagnostic methods, prognostic assessment, early detection o...

Non-invasive diagnosis and follow-up of primary biliary cholangitis.
https://doi.org/10.1016/j.clinre.2021.101770
Clinics and Research in Hepatology and Gastroenterology; Corpechot C, Heurgue A et. al.

Aug 1st, 2021 - Primary biliary cholangitis (PBC) is a chronic inflammatory disease of the intra-hepatic bile ducts [1]. It is characterised biologically by chronic cholestasis associated with the presence of specific autoantibodies, and histologically by lesions...

Non-invasive diagnosis and follow-up of primary sclerosing cholangitis.
https://doi.org/10.1016/j.clinre.2021.101775
Clinics and Research in Hepatology and Gastroenterology; Chazouillères O, Potier P et. al.

Aug 1st, 2021 - Primary sclerosing cholangitis (PSC) is a rare and chronic cholestatic liver disease of unknown cause commonly associated with inflammatory bowel disease (IBD) and characterized by progressive obliterative fibro-inflammation of the biliary tree. A...

ASGE guideline on the management of cholangitis.
https://doi.org/10.1016/j.gie.2020.12.032
Gastrointestinal Endoscopy; Buxbaum JL, Buitrago C et. al.

May 24th, 2021 - Cholangitis is a GI emergency requiring prompt recognition and treatment. The purpose of this document from the American Society for Gastrointestinal Endoscopy's (ASGE) Standards of Practice Committee is to provide an evidence-based approach for m...

COVID-19 Pandemic: Which IBD Patients Need to Be Scoped-Who Gets Scoped Now, Who Can Wa...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665406
Journal of Crohn's & Colitis; Ng SC, Mak JWY et. al.

Oct 22nd, 2020 - Endoscopy is an essential component in the management of inflammatory bowel disease [IBD]. There is a risk of SARS-CoV-2 transmission during endoscopic procedures. The International Organization for the study of IBD [IOIBD] has developed 11 positi...

see more →

Drugs  11 results see all →

Clinicaltrials.gov  339 results

Unraveling the Mechanisms Underlying Primary Sclerosing Cholangitis Through a Multidisciplinary, Integrative Research Approach
https://clinicaltrials.gov/ct2/show/NCT04685200

Mar 23rd, 2023 - Study Description: We hypothesize that primary sclerosing cholangitis (PSC) develops as a consequence of a genetically driven aberrant immune response to commensal or pathogenic bacteria, and that unique genetic-immunemicrobial associations may un...

A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness
https://clinicaltrials.gov/ct2/show/NCT05014672

Mar 21st, 2023 - The primary objective of this study is to evaluate the effect of setanaxib on biochemical response at Week 52 in participants with primary biliary cholangitis (PBC) and with elevated liver stiffness and intolerance or inadequate response to ursode...

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
https://clinicaltrials.gov/ct2/show/NCT01174121

Mar 17th, 2023 - Background: Metastatic digestive tract cancers, in particular esophageal, gastric, pancreatic and hepatobiliary carcinomas, are associated with poor survival beyond five years and poor response to existing therapies. Data from the National Cancer ...

Phase 2a Evaluation of Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC)
https://clinicaltrials.gov/ct2/show/NCT04480840

Mar 15th, 2023 - Three-part study: Part 1 - 12-week treatment period evaluating 40 mg of PLN-74809 or matching placebo [Complete] Part 2 - 12-week treatment period evaluating two dose groups, 80 mg and 160 mg of PLN-74809 or matching placebo Part 3 - minimum 24-we...

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC)
https://clinicaltrials.gov/ct2/show/NCT03301506

Mar 10th, 2023 - Primary: To evaluate the long-term safety and tolerability of seladelpar Secondary: To evaluate the long-term efficacy of seladelpar To evaluate the effect of seladelpar on patient-reported outcomes (pruritus)

see more →

News  334 results

Duodenoscopes With Disposable Caps Led to Less Microbial Contamination
https://www.medpagetoday.com/gastroenterology/generalgastroenterology/102764

Jan 23rd, 2023 - Use of duodenoscopes with disposable elevator caps during endoscopic retrograde cholangiopancreatography (ERCP) led to lower rates of contamination following high-level disinfection compared with standard scope designs, and did not affect the tech...

Genomics data reveal promising PSC therapeutic target
https://www.mdedge.com/gihepnews/article/260476/pancreas-and-biliary-tract/genomics-data-reveal-promising-psc-therapeutic
Tara Haelle, MDedge News

Jan 4th, 2023 - An investigation of genomics data related to primary sclerosing cholangitis (PSC) in published medical literature revealed several genes likely involved in the pathogenesis of this autoimmune diseases, according to a study published in Gastro Hep.

Hyaluronidase for Skin Necrosis Induced by Amiodarone
https://www.mdedge.com/dermatology/article/259180/wounds/hyaluronidase-skin-necrosis-induced-amiodarone
Hannah Y. Wang, BS, Joanne S. Jacob, MD et. al.

Nov 3rd, 2022 - To the Editor: Amiodarone is an oral or intravenous (IV) drug commonly used to treat supraventricular and ventricular arrhythmia as well as atrial fibrillation. 1 Adverse drug reactions associated with the use of amiodarone include pulmonary, gastr.

177Lu-FAP-2286 Displays Preliminary Antitumor Activity in Advanced or Metastatic Solid Tumors
https://www.onclive.com/view/177lu-fap-2286-displays-preliminary-antitumor-activity-in-advanced-or-metastatic-solid-tumors

Oct 18th, 2022 - The targeted radiotherapy candidate lutetium-177-FAP-2286 (177Lu-FAP-2286) produced preliminary evidence of antitumor activity with a manageable safety profile in patients with advanced or metastatic solid tumors, according to data from the phase ...

Treatment Options for Early-Stage Biliary Tract Cancers
https://www.onclive.com/view/treatment-options-for-early-stage-biliary-tract-cancers

Oct 13th, 2022 - Transcript: Milind Javle, MD: Flavio, you raise important issues. I also wonder about the role of surgery in some of these patients who have MSI [microsatellite instability]–high, but we should move on. As I expected, this panel has a lot to say ...

see more →

Patient Education  28 results see all →